Close Lightbox

Close Lightbox

Skip to content
  • DOW
    /
  • Nasdaq
    /
  • S&P
    /
Primary Menu ☰
    • My Services
    • Manage Account
    • Support
    • Logout
  • Our Products
  • Our Analysts
  • Education Center
  • Free Content
  • Market Analysis
    • Stock Picks
    • Market Insight
    • Crypto
    • Stocks to Buy
    • Hot Stocks
  • About InvestorPlace
    Log out
    • My Services
    • Manage Account
    • Support
    • Logout
    • Home
      • /
    • Hot Topics
      • /
    • AKCA

    AKCA

    Akcea Therapeutics News: AKCA Stock Rockets on Pfizer Licensing Deal

    By William White, InvestorPlace Writer Oct 7, 2019
    Akcea Therapeutics (AKCA) stock is flying high on Monday following news of a $250 million deal with Pfizer (NYSE:PFE) for licensing rights.

    • Most Recent

      1. Market Insight

        Feb 09, 2026

        The Quiet Bull Case Building Beneath the Headlines

      2. Market Insight

        Feb 09, 2026

        Hershey Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks

      3. Market Insight

        Feb 09, 2026

        The Easy AI Money Is Over, but the Bigger Gains Come Next

      4. Market Insight

        Feb 08, 2026

        Don’t Chase Yesterday’s AI Winners – Buy Tomorrow’s

      5. Market Insight

        Feb 08, 2026

        2 Stocks to Buy for AI’s Next Stage

    • About InvestorPlace
    • Products
    • Contact Us
    • Help
    • Careers
    • Disclosures & Disclaimers
    • Privacy Policy
    • Ad Choices
    • Do Not Sell My Personal Information
    • Cookie Policy
    • Cookie Preferences
    • Terms of Use
    • DMCA Policy

    All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Copyright © 2026 InvestorPlace Media, LLC. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201.

    Subscriber Sign in

    Forgot Password?

    Not Yet a Premium Subscriber?

    Subscribe

    Swipe DOE IP Logo

    Your Email